Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Lupus erythematosus
(1980): Condemi JJ, Geriatrics 35(3), 81
Lymphocytoma cutis
(1988): Raymond JZ+, Cutis 41, 323
Necrotizing vasculitis
Perforating foot ulceration
(1997): Bouloc A+, Clin Exp Dermatol 21, 351
Petechiae
Photosensitivity
(1986): Lerman S, Ophthalmology 93, 304
Pityriasis rosea
(2006): Atzori L+, Dermatology Online Journal 12(1), 1 (with
hydrochlorothiazide)
Pruritus (10%)
Pustules
(2002): Lun K+, Australas J Dermatol 43(2), 140
Pustuloderma
(1994): Fitzgerald DA+, Clin Exp Dermatol 19, 243
Rash (sic) (>10%)
(2005): Choi SH+, Korean J Hepatol 11(1), 80
(2003): Mete N+, J Investig Allergol Clin Immunol 13(4), 281
(2001): Dominguez Ortega J+, An Med Intern 18(1), 27
(1996): Yale SH+, Hosp Pract Off Ed 31, 92
Sensitivity (sic)
Stevens–Johnson syndrome (>10%)
(2007): Dainichi T+, Dermatology 215(1), 86
(2005): Lin MS+, Intern Med J 35(3), 188
(2003): Fine P+, Optometry 74(10), 659
(2003): Yeung CK+, Acta Derm Venereol 83(3), 179 (8 cases)
(1999): Halevy S+, Int J Dermatol 38(11), 835
(1995): Gonzalez U+, Rev Invest Clin 47(5), 409
(1995): Roujeau JC+, NEnglJMed333(24), 1600
(1993): Leenutaphong V+, Int J Dermatol 32, 428
(1992): Goodglick TA+, Ophthalmic Surg 23, 557
(1989): Chan SH+, Dermatologica 179, 32
(1985): Edwards R+, Dimens Crit Care Nurs 4, 335
(1985): Renwick IG, BMJ 291, 485
(1985): Ting HC+, Int J Dermatol 24, 587
(1984): Pennell DJ+, Lancet 1, 463 (fatal)
Toxic epidermal necrolysis
(2007): Dainichi T+, Dermatology 215(1), 86
(2007): Paquet P+, Burns 33(1), 100
(2005): Kakeda M+, JDermatol32(8), 654
(2005): Lin MS+, Intern Med J 35(3), 188
(2005): Nasser M+, Am J Med Sci 329(2), 95
(2003): Yeung CK+, Acta Derm Venereol 83(3), 179 (8 cases)
(2002): Correia O+, Arch Dermatol 138, 29 (2 cases)
(2001): Hammer B+, Dtsch Med Wochenschr 126(47), 1331
(1999): Sorkin MJ, Denver, CO (from Internet) (observation)
(1995): Roujeau JC+, NEnglJMed333(24), 1600
(1995): Wolkenstein P+, Arch Dermatol 131, 544
(1994): Alfandari S+, Infection 22, 365
(1993): Correia O+, Dermatology 186, 32
(1993): Leenutaphong V+, Int J Dermatol 32, 428
(1991): Sakellariou G+, Int J Artif Organs 14, 634
(1987): Guillaume JC+, Arch Dermatol 123, 1166
(1986): Kumar L, Indian J Dermatol 31, 53
(1985): Auboeck J+, BMJ 290, 1969
(1985): Renwick IG, BMJ 291, 485
(1985): Zakraoui L+, Tunis Med (French) 63, 167
(1984): Chan HL, JAmAcadDermatol10, 973
(1984): Dan M+, Int J Dermatol 23, 142
Toxic erythema
ALLOPURINOL 17
(1995): Rademaker M, NZMedJ108, 165
Toxic pustuloderma
(1994): Boffa MJ+, Br J Dermatol 131, 447
(1994): Fitzgerald DA+, Clin Exp Dermatol 19, 243
(1993): Yu RC+, Br J Dermatol 128, 95
Urticaria (>10%)
(2001): Dominguez Ortega J+, An Med Interna 18(1), 27
(1999): Litt JZ, Beachwood, OH (personal case) (observation)
(1992): Breathnach SM+, Adverse Drug Reactions and the Skin
Blackwell, Oxford, 193 (passim)
(1991): Anderson MH+, Ann Allergy 66, 207
Vasculitis (